Epidermal growth factor receptor (EGFR) tyrosine kinase uncommon mutations (EGFR)

The Epidermal Growth Factor Receptor (EGFR) is a transmembrane protein with intrinsic tyrosine kinase activity that plays a critical role in regulating cell growth, survival, and differentiation through the MAPK, PI3K/Akt, and STAT pathways. While common mutations like exon 19 deletions and the L858R point mutation account for the majority of EGFR-mutated non-small cell lung cancers (NSCLC), 'uncommon' mutations represent a heterogeneous group comprising approximately 10-15% of cases. These include point mutations such as G719X, L861Q, and S768I, as well as exon 20 insertions, which often exhibit different sensitivities to standard first- and second-generation tyrosine kinase inhibitors (TKIs). Targeting these uncommon variants is clinically challenging because many, particularly exon 20 insertions, create a restricted binding pocket that confers primary resistance to early-generation TKIs like erlotinib or gefitinib. Second-generation irreversible TKIs like afatinib have shown efficacy against G719X, L861Q, and S768I, while newer agents like amivantamab (a bispecific antibody) and specialized TKIs like mobocertinib were specifically developed to address the structural constraints of exon 20 insertions. Understanding the specific molecular profile of these uncommon mutations is essential for selecting the most effective therapeutic strategy and improving patient outcomes in precision oncology.

Other names

ErbB-1HER1Uncommon EGFR mutationsAtypical EGFR mutationsEGFR exon 20 insertionsEGFR G719XEGFR L861QEGFR S768I

Tyrosine kinase inhibitors (TKIs) bind to the ATP-binding pocket of the EGFR intracellular domain, preventing autophosphorylation and downstream signaling; monoclonal antibodies bind the extracellular domain to block ligand binding and induce receptor internalization.